Holen Sie sich die Stockscreener-App
5.435
2.54%
0.125
Schlusskurs vom Vortag:
$5.31
Offen:
$5.31
24-Stunden-Volumen:
2.68M
Relative Volume:
0.65
Marktkapitalisierung:
$884.16M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
135.88
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
+20.46%
1M Leistung:
+68.58%
6M Leistung:
+598.08%
1J Leistung:
+46.37%
1-Tages-Spanne:
$5.15
$5.565
1-Wochen-Bereich:
$4.171
$5.565
52-Wochen-Spanne:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
5.435 | 863.82M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.65 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Zacks Research Issues Optimistic Forecast for IRWD Earnings - MarketBeat
Returns Recap: Can Ironwood Pharmaceuticals Inc. stock double in the next year2025 Earnings Impact & Daily Momentum Trading Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 8.4%Here's Why - MarketBeat
Zacks Research Has Positive Outlook for IRWD Q4 Earnings - MarketBeat
Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients - MSN
Weekly Earnings: Is Ironwood Pharmaceuticals Inc forming a breakout patternJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Aug Weekly: Is Ironwood Pharmaceuticals Inc forming a breakout patternPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.4%Here's Why - MarketBeat
Insider Sell: Should you avoid Ironwood Pharmaceuticals Inc. stock right nowMarket Sentiment Review & Entry Point Strategy Guides - baoquankhu1.vn
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 94.00% to 4.95 - Nasdaq
Growth Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSWeekly Market Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 10.7%Here's What Happened - MarketBeat
Winners Losers: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentJuly 2025 Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-10 17:20:03 - Улправда
Ironwood Pharma resolves Ferring dispute, amends license terms - MSN
Ironwood stock rises 27% on upbeat revenue guidance for 2026 - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat
5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Yahoo Finance
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Craig Hallum - MarketBeat
Why did Ironwood Pharmaceuticals stock skyrocket today? - MSN
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 32% Share Price Rise - 富途牛牛
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) - Nasdaq
Craig-Hallum Boosts Ironwood (IRWD) Rating with Optimistic Outlo - GuruFocus
Wells Fargo Raises Target Price for IRWD to $5.00 Maintaining Eq - GuruFocus
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 - Finviz
Wells Fargo & Company Forecasts Strong Price Appreciation for Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The Five-year Loss for Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Likely Driven by Its Shrinking Earnings - 富途牛牛
Ironwood Pharmaceuticals (IRWD) Upgraded to Market Outperform by Citizens | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift - TechStock²
Ironwood Pharmaceuticals stock price target raised to $5 by Wells Fargo - Investing.com Canada
Citizens upgrades Ironwood Pharmaceuticals stock rating on LINZESS strength By Investing.com - Investing.com Canada
Promising Pharmaceutical Stocks To ConsiderJanuary 2nd - MarketBeat
Ironwood Pharmaceuticals Surges on Linzess Sales Boost - StocksToTrade
Ironwood Pharmaceuticals’ Stock Surges as Higher Linzess Sales Drive Market Excitement - timothysykes.com
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook - TechStock²
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? - Asianet Newsable
Ironwood Pharma leaps on 2025/2026 guidance - The Pharma Letter
Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
Ironwood Pharma (IRWD) Surges on Strong FY26 Guidance and Pipeli - GuruFocus
Stock soars at Boston biotech after it cuts price of IBS drug - The Business Journals
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):